D
espite recent advances in our understanding of the pathophysiology of sepsis, the ideal management of septic shock remains controversial. In large patienttrials, a variety of therapeutic strategies have been investigated without significantly improved outcomes (1, 2) . There is general agreement that there is depressed vasoconstrictor sensitivity to catecholamines in septic shock that can lead to vasodilation and severe hypotension (3, 4) . Moreover, persistent vasodilation and hypotension have been associated with poor outcome in patients with severe sepsis (5, 6) . Thus, efforts commonly are directed toward increasing blood pressure with vasopressor agents in these patients. Escalating doses of exogenous catecholamines, often massive doses, generally are used (7) . However, recent case reports and small clinical trials suggest that low-dose vasopressin may be an effective alternative to traditional highdose catecholamine therapy for increasing systemic resistance and blood pressure in septic patients (8 -10 ).
Vasopressin's secretion normally is involved in regulation of plasma osmolarity, via its renal antidiuretic action (11) . However, numerous recent studies indicate that plasma concentrations of vasopressin are increased dramatically in certain stressful situations such as hemorrhagic (12) and septic shock (13, 14) , and it appears that endogenous vasopressin is important in maintaining blood pressure in these conditions via its vasoconstricting action. Indeed, pretreatment with a vasopressin antagonist specific for the vascular receptor increased the hypotensive effects of endotoxin treatment in rats (15) , and exogenous vasopressin therapy increased blood pressure and decreased early mortality in endotoxin-treated rats (16) .
In addition to vasopressin's direct vasoconstricting action, subconstricting doses of vasopressin appear to enhance the pressor response to catecholamines (17) (18) (19) . Similarly, we recently reported that low-dose vasopressin reversed the hyporesponsiveness of human gastroepiploic arteries to norepinephrine after treatment with endotoxin (20) .
The aims of the present study were to determine the cardiovascular and metabolic effects of low-dose intravenous vasopressin in a group of septic patients with persistent hypotension despite infusions of pharmacologic doses of catecholamines.
METHODS

Patient Selection
The study was conducted in accordance with the recommendations of the Ethics Com-mittee of Kagoshima University Hospital. After we obtained informed consent from the closest relative, 16 patients diagnosed with septic shock who remained hypotensive despite continuous infusion of pharmacological doses of catecholamine were entered into the study. Clinical data relating to the patients are given in Table 1 We excluded patients with hypovolemia (i.e., central venous pressure Ͻ7 mm Hg or PAOP Ͻ10 mm Hg), a history of coronary disease, or either a known history of heart failure or hemodynamic evidence of heart failure (cardiac index [CI] Ͻ2.5 L/min/m 2 despite PAOP Ͼ10 mm Hg, or known left ventricular ejection fraction Ͻ50% by echocardiography).
Study Protocol
Vasopressin (Pitressin) was infused for 16 hrs through a central venous catheter at a fixed rate of 0.04 units/min. The 16-hr period for vasopressin infusions was chosen to allow a sufficient period for the plasma vasopressin concentration to reach steady-state levels and the vasopressin-induced effects to fully develop. The vasopressin was administered through a route independent of that used for other vasoactive and inotropic drugs. During the initial 16-hr study period, continued treatment with vasopressin and other therapies was determined by the clinicians caring for the patients. However, caregivers were asked not to alter the amounts of the other vasoactive drugs infused or the rate of fluid administration unless indicated. As indicated in the Results, two patients remained hypotensive despite the vasopressin therapy, and additional fluid and increased amounts of norepinephrine infused were administered in attempts to stabilize these patients. The initial protocol called for discontinuation of the vasopressin at the end of the 16-hr trial. However (as also discussed in the Results), discontinuation (rapid tapering) of the vasopressin infusion at the end of the 16-hr trial in the first nine patients resulted in significant hypotension. Vasopressin infusions were restarted in these patients, and the vasopressin infusions were tapered more gradually in these and the subsequent subjects.
Monitoring and Measured Parameters
All patients were monitored by using continuous electrocardiography with automatic ST segment monitoring and arrhythmia detection in two leads (II and MCL1). Event detection was set to detect Ͼ1 mm ST segment elevation or depression and any noteworthy change in heart rate or rhythm. Blood pressure was monitored continuously and recorded by using an indwelling arterial catheter. Oxygen saturation was obtained continuously from a pulse oximeter. Measurements of hemodynamic parameters including cardiac output by thermodilution were recorded before and every 2 hrs after initiating the vaso- (5) MOF score, multiple organ failure score; MAP, mean arterial pressure; DOA, dopamine; DOB, dobutamine; NE, norepinephrine; EP, epinephrine; VP, vasopressin; s/p, status post; MRSA, methicillin-resistant Staphylococcus aureus; Outcome, ϩ alive, Ϫ deceased. pressin infusion by using a mixed venous oxygen saturation pulmonary artery catheter.
Arterial and venous blood was drawn before and every 4 hrs after initiating the vasopressin infusion to measure oxygen delivery and consumption parameters, electrolytes, hemoglobin, blood sugar, and plasma lactate.
Blood samples for subsequent determination of plasma concentrations of vasopressin by radioimmunoassay, as well as concentrations of atrial natriuretic peptide, aldosterone, angiotensin II, and renin, were taken before and at the end of the 16-hr vasopressin infusion.
Complications and Withdrawal From the Study
The study protocol called for discontinuing the vasopressin infusion and withdrawal from the study if patients developed any clinical evidence of myocardial, skin, intestinal, or hepatic ischemia. Myocardial ischemia was monitored by automated electrocardiogram analysis and hemodynamic monitoring as previously described, skin ischemia was monitored with physical exam, and intestinal and hepatic ischemia was monitored with frequent analysis of serum lactate concentrations as previously described and history or physical exam evidence of worsening abdominal pain, distension, tenderness, or bloody stool. In addition, the clinicians caring for the patientswho knew both that the patients were receiving experimental vasopressin infusions and the potential complications associated with this therapy-had the option to discontinue the vasopressin and withdraw the patient from the study for any reason.
Statistical Analysis
Results are expressed as mean Ϯ SD. Statistics were analyzed by using Statview 4.58 (Abacus Concepts, Berkeley, CA). A repeatedmeasures analysis of variance, followed by a paired Student's t-test, was used to compare the values obtained during each measurement period with the preinfusion values. Statistical significance was defined as p Ͻ .05.
RESULTS
Patient demographic information including diagnoses, identified infectious etiologies of septic shock, multiple organ failure scores, MAP, and pressor requirements for each patient at the time of entry into the study are shown in Table 1 . Also shown are overall duration of vasopressin infusions and outcome (survival).
Hemodynamic Effects of the Vasopressin Infusion
The hemodynamic changes (mean Ϯ SD) after the initiation of the vasopressin infusion are shown in Figure 1 (Fig. 1) . Similarly, there was no significant change in the CI, heart rate, PAOP, and central venous pressure measured before and at the end of the 16-hr vasopressin infusion: CI ϭ 4.1 Ϯ 1.8 and 4.2 Ϯ 1.6 L/min/m 2 ; heart rate ϭ 112 Ϯ 14.3 and 106 Ϯ 15.2 beats/min; PAOP ϭ 12.1 Ϯ 3.1 and 13.1 Ϯ 3.2 mm Hg; central venous pressure ϭ 11.5 Ϯ 3.4 and 11.9 Ϯ 3.8 mm Hg (baseline and 16-hr infusion values, respectively,).
Two of the 16 patients (patients 8 and 10) remained unstable with persistent hypotension after we initiated the vasopressin. These patients were given additional fluid boluses and increases in the rate of norepinephrine being administered by continuous infusion. The remaining 14 patients were stabilized by the vasopressin infusion and did not require any further increases in pressors or any additional fluid boluses during the 16-hr study period.
In the first nine patients, attempts to discontinue the vasopressin infusion at the end of the 16-hr study period resulted in significant declines in SAP (119 Ϯ 24.1 to 80.7 Ϯ 22.4 mm Hg; p Ͻ .05) over the first 30 mins (Fig. 2) .
Vasopressin was resumed in these patients, and subsequent attempts to decrease the vasopressin infusions were repeated every hour until the patients tolerated weaning and removal of the drug without a decrease in SAP below 90 mm Hg. As a result, the vasopressin infusions were continued in all the patients beyond the initial 16-hr study period with a range of infusion durations from 18 to 284 hrs and an average duration of 93 Ϯ 75 hrs (Table 1) .
Myocardial ischemia, cardiac dysfunction, and ventricular arrhythmias are complications reported with the use of vasopressin (21) . In our patients, we detected no noteworthy ST-T wave changes or arrhythmias, nor were there any decreases in cardiac output or unexplained increases in PAOP observed during the study period. Thus, we did not detect any cardiac complications in the patients receiving vasopressin in this study. 
Metabolic Effects of the Vasopressin Infusion
The metabolic parameters and electrolyte values obtained before and during the vasopressin infusion in the 16 patients are shown in Table 2 . There were no significant changes in any of these measurements over the 16-hr study period in the 16 patients as a group. However 
Urine Output During the Vasopressin Infusion
Urine output of the 16 patients before and during the 16-hr vasopressin infusion is shown in Figure 3 . Six of the 16 patients were anuric before we initiated the vasopressin infusion, and urine output did not increase in those patients. In the other ten patients, however, urine output increased and the overall increase in urine output for all 16 patients at the end of the 16-hr vasopressin infusion was significant (p Ͻ .01).
Hormonal Changes
The changes in the concentrations of the endogenous hormones are summarized in Table 3 . With the exception of the plasma concentration of vasopressinwhich increased from a baseline value of 7.3 Ϯ 8.5 to 289.3 Ϯ 64.7 pg/mL during the vasopressin infusion-there were no significant changes in the concentrations of atrial natriuretic peptide, aldosterone, angiotensin II, or renin during the 16-hr vasopressin treatment period.
Complications and Outcome
As discussed previously, two patients remained hypotensive despite administration of the vasopressin infusion. Both patients received additional fluid boluses and increases in the rate of the norepinephrine infusions. One of these patients (patient 10) had severe adult respiratory distress syndrome with refractory hypoxia and died 20 hrs after the start of the vasopressin infusion. The other patient (patient 8) had delayed hemorrhage from a liver laceration and died 2 days after entering the study. Of the remaining 14 patients, there were five additional deaths, all from multiple organ failure, that occurred over a 17-day period after entry into the vasopressin infusion study. The overall mortality was 44%.
There were no episodes of myocardial ischemia detected from the continuous electrocardiogram monitoring and automated ST segment analysis, and there were no arrhythmias or hemodynamic evidence of myocardial ischemia. There was no clinical evidence of skin or intestinal ischemia, and none of the clinicians caring for the patients elected to withdraw any of the patients from the study for any reason. There was no evidence that the vasopressin infusion contributed to the poor outcome in the patients who died.
DISCUSSION
The present study clearly demonstrates that low-dose vasopressin infu- sions produce clinically important increases in blood pressure and systemic resistance in hypotensive patients with vasodilatory septic shock. The patients studied were quite hypotensive (SAP Ͻ80 mm Hg) despite pharmacologic doses of catecholamines before vasopressin. After initiation of the vasopressin infusion, the increase in blood pressure was sufficient in the majority of these patients so that no further increases in any of the other pressors were necessary. As in prior studies (8, 9) , an untreated (placebo) group was not possible because the patients were all sufficiently hypotensive that some pressor therapy was indicated. Thus, it may not be possible to firmly conclude that the initial increases in blood pressure were entirely attributable to the vasopressin infusions. However, the responses we observed after discontinuing (and then restarting) the vasopressin infusion during the trial provided additional evidence that the vasopressin infusion was responsible for the increases in blood pressure observed. Indeed, blood pressure returned to pretreatment levels when the infusion was discontinued and returned to posttreatment levels when the infusion was again resumed (Fig. 2) . This additional evidence provides clear proof that the vasopressin infusion was responsible for the effects on blood pressure and systemic resistance observed. The results of the present study support the findings of Landry et al. (8, 9) , who also recently reported on the effectiveness of low-dose vasopressin infusions in patients with vasodilatory septic shock. We did not, however, observe any decreases in cardiac output during the vasopressin infusions as reported by that group. Except for a coronary constricting effect, which could lead to ischemic cardiac dysfunction, vasopressin is known to have little direct effect on heart function (21). Nevertheless, vasopressin generally is observed to decrease cardiac output in normal subjects. This effect has been attributed to baroreflexes, which blunt important increases in blood pressure despite vasopressin-induced vasoconstriction (22) (23) (24) . In our patients, blood pressure remained relatively low during the vasopressin infusions, and baroreflexmediated decreases in cardiac output thus would not be expected. In contrast, the blood pressures in the patients studied by Landry et al. (8, 9) were considerably higher both before and during the vasopressin infusions, and baroreflexes thus could have played a role in the decreases in cardiac output observed in their patients.
Concentrations of vasopressin Ͼ300 pg/mL generally are required to elicit any noteworthy elevation in blood pressure in normal subjects (24) . However, the vasoconstricting effects of vasopressin clearly are underestimated by the pressor response because of efficient use of baroreflexes that buffer the increases in systemic resistance, as discussed previously. (26) or cardiopulmonary bypass (27) . In addition to its welldocumented direct vasoconstricting action, several studies indicate that vasopressin also potentiates the constricting effects of catecholamines even at vasopressin doses that have no measurable constricting effect alone (17) (18) (19) (20) . We recently demonstrated that vasopressinacting through its vascular receptorenhanced the contraction of both normal and endotoxin-treated human gastroepiploic arteries to norepinephrine (20) . The enhancing effect became evident even at relatively low concentrations (Ϸ50 pg/ mL) and reached a maximum at Ϸ500 pg/mL. In the present study, the vasopressin infusions produced a plasma concentration of nearly 300 pg/mL, a concentration that would be expected to have some direct constricting effect. It seems likely, however, that the vasoconstrictor effect of vasopressin observed in our patients also may reflect the potentiating effect of vasopressin on responses to both endogenous and infused catecholamines.
Consistent with this view
Hypotension is a very potent stimulus for the release of endogenous vasopressin. Plasma levels Ͼ100 pg/mL are reported in hemorrhagic and septic shock, and vasopressin in these conditions appears to be an important determinant in maintaining blood pressure (12) (13) (14) . Thus, the levels of Ϸ7 pg/mL that we measured at baseline appear to be abnormally low, particularly given the degree of hypotension present in these patients. Landry et al. (9) presented similar data and a compelling argument that vasopressin responses are abnormally low in septic patients, possibly because of impaired secretion or vasopressin depletion. Similar results have been obtained after prolonged hemorrhage in animals, where vasopressin depletion appears to contribute to persistent hypotension after restoring intravascular volume (12) . Vasopressin thus may be particularly important in reestablishing cardiovascular homeostasis and vascular responsiveness in septic patients, which may be depressed in part because of vasopressin depletion or abnormal release of endogenous vasopressin. This also may partly explain the additional observation that although catecholamine-induced vasoconstriction is attenuated in septic animals, the vaso- constrictor action of vasopressin is enhanced (13, 28) . Another major finding of the present study was the increase in urine output that occurred during the vasopressin infusion. Vasopressin is best known as "antidiuretic hormone," with the maximal antidiuretic action achieved in the 5-10 pg/mL range (29) . In contrast, levels Ͼ100 pg/mL produced by vasopressin infusions have a well-documented naturetic action (30) , which could have contributed to the increased urine output observed in this and prior studies (8, 9, 31, 32) . Vasopressin also regulates the release of other mediators including atrial natriuretic peptide, renin, angiotensin II, and aldosterone (33, 34) that also might be involved in this effect, although we observed no difference in the plasma concentrations of these mediators during the vasopressin infusions in this study. Because the positive effect on blood pressure would by itself be expected to increase urine output (35) (36) (37) , it is difficult to draw any firm conclusions regarding the mechanisms underlying the improved urine output during vasopressin infusions in this study. Because vasopressin has a relatively small renal constricting effect (38) , vasopressin infusions could prove advantageous compared with adrenergic agonists in controlling hypotension in septic patients by providing better preservation of renal blood flow. This potential advantage of vasopressin over conventional catecholamine therapy, however, will need to be clarified in a future comparative trial.
In this study we did not observe evidence of myocardial ischemia in any of the patients during the 16-hr study period, and there were no significant changes in any of the metabolic parameters of oxygen delivery and consumption measured during the infusions. Our lactate data are similar to those of previous studies with little change in lactate concentrations in the first 16 -24 hrs of therapy (39, 40) . Thus, vasopressin did not appear to ameliorate the metabolic or microcirculatory derangements responsible for the elevated lactate concentrations in the time interval studied (16 hrs). However, neither did vasopressin appear to make the situation any worse than expected. Plasma lactate concentrations reflect the balance between lactate production and lactate clearance. Indeed, both increased tissue lactate production and decreased hepatic clearance may contribute to the elevated lactate concentrations seen in septic patients (39, 40) . Lactate concentrations frequently are followed in septic patients to indicate worsening in either process (i.e., increased production signaling worsening tissue hypoxia or decreased clearance that may indicate liver impairment). Although we could not exclude balanced effects (e.g., simultaneous increased tissue lactate production and increased lactate clearance), this seems unlikely. Rather, the lack of any increases in lactate concentrations during the vasopressin infusions most likely indicates that tissue hypoxemia did not worsen and hepatic clearance did not decrease in our patients. As in prior studies, lactate concentrations were significantly higher in the nonsurvivor patients compared with the survivor group. However, there is considerable overlap in lactate concentrations between survivors and nonsurvivors. Nevertheless, our data agree with prior studies indicating that lactate concentrations may have prognostic value in septic patients (39, 40) . In addition, our data suggest that changes in lactate concentrations over time rather than isolated measurements may be a more sensitive predictor of outcome.
In summary, our data, as well as recent reports from another group, strongly suggest that low-dose vasopressin could be used as an alternative to the more traditional high-dose catecholamine therapies used in septic patients with vascular hyporeactivity to catecholamines. The direct vasoconstricting effect of vasopressin may be particularly important, and/or vasopressin may be essential to maintain catecholamine responsiveness in septic patients. Our data do not indicate any clear benefit of vasopressin beyond the increases in blood pressure and systemic resistance. Thus, there was no evidence that vasopressin helped resolve the shock state itself. Urine output increased, but this effect may be nonspecific. The elevated baseline lactate concentrations decreased, but the change was not significant. Survival was similar to that recently reported with conventional therapy (7) . Clearly, differences between vasopressin and conventional high-dose catecholamine therapy for control of blood pressure cannot be addressed adequately by an uncontrolled trial such as this. The ways that outcome and other measured variables would differ in patients treated with vasopressin vs. traditional therapies can only be determined by a randomized controlled trial. Given the similarities in responses and outcome, such a study will likely require a much larger patient sample size and potentially would best be accomplished with a multicenter design. 
